Tasdelen Fisgin N, Ergonul O, Doganci L, Tulek N
Faculty of Medicine, Department of Clinical Microbiology and Infectious Diseases, Ondokuz Mayis University, Samsun, Turkey.
Eur J Clin Microbiol Infect Dis. 2009 Aug;28(8):929-33. doi: 10.1007/s10096-009-0728-2. Epub 2009 Mar 20.
Crimean-Congo hemorrhagic fever (CCHF) is a disease with high fatality. To demonstrate the effectiveness of ribavirin against CCHF. The first group of 21 patients received ribavirin within 4 days of the onset of symptoms (early use of ribavirin, EUR); the second group of 20 patients received ribavirin > or =5 days after the onset of the symptoms of the disease (late use of ribavirin, LUR); and the last group of 11 patients did not receive ribavirin (no use of ribavirin, NUR). At 5-10 days from the onset of symptoms the mean platelet counts of the patients in the EUR group were significantly higher than those of the patients in LUR group, and at 7-9 days, they were significantly higher than that of the patients in the NUR group. The mean aspartate transferase levels in the EUR group were significantly lower than of the NUR group on days 8 and 9, and the mean alanine transferase level was significantly lower on day 8 after the onset of the symptoms. There is a beneficial effect of ribavirin if given at an early phase of the CCHF. We suggest ribavirin use especially in the early phase of the disease.
克里米亚-刚果出血热（CCHF）是一种致死率很高的疾病。为了证明利巴韦林对CCHF的疗效，第一组21例患者在症状出现后4天内接受利巴韦林治疗（早期使用利巴韦林，EUR）；第二组20例患者在疾病症状出现后≥5天接受利巴韦林治疗（晚期使用利巴韦林，LUR）；最后一组11例患者未接受利巴韦林治疗（未使用利巴韦林，NUR）。在症状出现后5-10天，EUR组患者的平均血小板计数显著高于LUR组患者，在7-9天，显著高于NUR组患者。在症状出现后的第8天和第9天，EUR组的平均天冬氨酸转氨酶水平显著低于NUR组，症状出现后第8天平均丙氨酸转氨酶水平显著降低。在CCHF早期给予利巴韦林有有益作用。我们建议尤其在疾病早期使用利巴韦林。
